Title
Persistently elevated C-reactive protein level in the first year of antiretroviral therapy, despite virologic suppression, is associated with HIV disease progression in resource-constrained settings
Date Issued
01 April 2016
Access level
open access
Resource Type
journal article
Author(s)
Shivakoti R.
Yang W.T.
Berendes S.
Mwelase N.
Kanyama C.
Pillay S.
Samaneka W.
Santos B.
Poongulali S.
Tripathy S.
Riviere C.
Cardoso S.W.
Sugandhavesa P.
Balagopal A.
Gupte N.
Semba R.D.
Campbell T.B.
Bollinger R.C.
Gupta A.
Publisher(s)
Oxford University Press
Abstract
A case-cohort analysis of human immunodeficiency virus (HIV)-infected individuals receiving antiretroviral therapy (ART) was performed within a multicountry randomized trial (PEARLS) to assess the prevalence of persistently elevated C-reactive protein (CRP) levels, based on serialmeasurements of CRP levels, and their association with HIV clinical failure. A persistently elevated CRP level in plasma (defined as ≥5 mg/L at both baseline and 24 weeks after ART initiation) was observed in 50 of 205 individuals (24%). A persistently elevated CRP level but not an elevated CRP level only at a single time point was independently associated with increased clinical failure, compared with a persistently low CRP level, despite achievement of virologic suppression. Serial monitoring of CRP levels could identify individuals who are at highest risk of HIV progression and may benefit from future adjunct antiinflammatory therapies.
Start page
1074
End page
1078
Volume
213
Issue
7
Language
English
OCDE Knowledge area
Virología
Epidemiología
Salud pública, Salud ambiental
Subjects
Scopus EID
2-s2.0-84962609078
PubMed ID
Source
Journal of Infectious Diseases
ISSN of the container
00221899
Sponsor(s)
We thank the PEARLS study participants, for volunteering their time and efforts. R. S. conceived the research question, conducted the data analysis, and wrote the primary version of the manuscript. W.-T. Y., N. G., R. C. B., and A. B. contributed to data interpretation and manuscript review. S. B., N. M., C. K., S. P., W. S., B. S., S. P., S. T., C. R., J. R. L., S. W. C., and P. S. contributed to data collection and manuscript review. R. D. S. contributed to study design, laboratory testing, and manuscript review. T. B. C. contributed to study design, data collection, oversight of study implementation, and manuscript review. A. G. obtained funding and contributed to study conception, design, and manuscript writing and review. All authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors and were fully responsible for all aspects of manuscript development. This work was supported by the NIAID (grants R01AI080417, UM1AI068636, UM1AI068634, UM1AI106701, and UM1AI069465), the National Institute of Mental Health, and the National Institute of Dental and Craniofacial Research, NIH. The parent trial, A5175, was also supported in part by Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline.
Sources of information:
Directorio de Producción Científica
Scopus